Quarterly ResultMay 14, 2026, 08:12 AM
Cingulate Q1 Cash $25.9M; CTx-1301 NDA Review Continues
AI Summary
Cingulate Inc. reported its first-quarter 2026 financial results, showing a strengthened balance sheet with cash and cash equivalents growing to $25.9 million as of March 31, 2026, an increase of $14.9 million from year-end 2025. This was driven by a $12.0 million private placement. The company is actively engaging with the FDA on its CTx-1301 NDA for ADHD, with a PDUFA target action date of May 31, 2026, and is advancing commercial readiness efforts. Despite an increased net loss of $9.3 million, management believes current capital funds operations into 2027.
Key Highlights
- Cash and cash equivalents increased to $25.9 million as of March 31, 2026.
- Working capital rose to $17.0 million from $1.7 million at year-end 2025.
- Successfully closed a $12.0 million private placement in February 2026.
- Net loss for Q1 2026 was $9.3 million, compared to $3.9 million in Q1 2025.
- General and administrative expenses increased to $5.7 million from $1.5 million YoY.
- R&D expenses decreased slightly by 1.8% to $2.2 million for Q1 2026.
- CTx-1301 NDA review continues with FDA, PDUFA target action date May 31, 2026.
- Cash runway extended into 2027, supporting key milestones.